Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Borel

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Seminars in Hematology|January 24, 2006
Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitorsRoseline d'Oiron, F Volot, J Reynaud, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 6, 2016
Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014Y Dargaud, A Pavlova, S Lacroix-Desmazes, et al.
Vox Sanguinis|December 15, 2017
Postauthorization safety study of Clottafact<sup>®</sup> , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational studyC Négrier, A-S Ducloy-Bouthors, V Piriou, et al.
Thrombosis and Haemostasis|December 8, 1998
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune toleranceC Rothschild, Y Laurian, E P Satre, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 18, 2017
Immunogenicity, efficacy and safety of Nuwiq<sup>®</sup> (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect StudyR J Liesner, M Abashidze, O Aleinikova, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Seminars in Hematology|January 24, 2006
Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitorsRoseline d'Oiron, F Volot, J Reynaud, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 6, 2016
Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014Y Dargaud, A Pavlova, S Lacroix-Desmazes, et al.
Vox Sanguinis|December 15, 2017
Postauthorization safety study of Clottafact<sup>®</sup> , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational studyC Négrier, A-S Ducloy-Bouthors, V Piriou, et al.
Thrombosis and Haemostasis|December 8, 1998
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune toleranceC Rothschild, Y Laurian, E P Satre, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 18, 2017
Immunogenicity, efficacy and safety of Nuwiq<sup>®</sup> (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect StudyR J Liesner, M Abashidze, O Aleinikova, et al.
Pageof 7